<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02455843</url>
  </required_header>
  <id_info>
    <org_study_id>ShandongPH Jinan</org_study_id>
    <nct_id>NCT02455843</nct_id>
  </id_info>
  <brief_title>Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC</brief_title>
  <official_title>A Multicenter, Randomized, Open-label Phase III Trial of Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Provincial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, randomized, open-label Phase III trial that compares microwave
      plus chemotherapy versus chemotherapy in patients with advanced non-small cell lung cancer.
      The primary endpoint is progression free survival (PFS) and the key secondary endpoint is
      overall survival (OS). A total of 275 eligible patients will be randomized to receive either
      microwave ablation combinated with first-line platinum-based doublet chemotherapy（138） or
      first-line platinum-based doublet chemotherapy（137） in a 1:1 ratio until patients. The
      response of microwave ablation will be assessed by the expert consensus for thermal ablation
      of primary and metastatic lung tumors. Tumor response and progression will be assessed
      according to Response Evaluation Criteria in Solid Tumors（RECIST）1.1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to treated with microwave ablation and chemotherapy or treated
      with chemotherapy alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients were divided into two groups: The microwave ablation plus chemotherapy group and the chemotherapy group.The former will be treated with microwave, followed by chemotherapy.The latter will be treated with chemotherapy alone.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>up to 12 months after the last patient randomized</time_frame>
    <description>From the start of chemotherapy or ablation to the date of progression or death</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">275</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Microwave plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In combination group, patients will be treated with microwave ablation in primary tumor sites followed by chemotherapy （For non-squamous cell lung cancer，patients will be treated with pemetrexed，500mg/m2, d1, ivdrip, or docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, ivdrip,or novelbine 25mg/m2 d1 d8, ivdrip, paclitaxel 175mg/m2 d1 ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip. For squamous cell lung cancer，patients will be treated with docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip；repeated every 3 weeks and up to 6 cycles are administrated ）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In chemotherapy group,patients will be treated with chemotherapy alone（For non-squamous cell lung cancer，patients will be treated with pemetrexed，500mg/m2, d1, ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with a area uder the curve of 5 d1 ivdrip. For squamous cell lung cancer，patients will be treated with docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, novelbine 25mg/m2 d1 d8, ivdrip, paclitaxel 175mg/m2 d1 ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip；repeated every 3 weeks and up to 6 cycles are administrated ）</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Microwave ablation</intervention_name>
    <description>Patients assigned to the combination group will be treated with microwave in the primary tumor site</description>
    <arm_group_label>Microwave plus chemotherapy</arm_group_label>
    <arm_group_label>chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of advanced stage NSCLC (stage IIIB or IV) which is confirmed by histology
             or cytology methods.

          2. Measurable disease other than the primary tumors site according to RECIST1.1.

          3. Eastern Cooperative Oncology Group (ECOG) score of 0-2

          4. Adequate organ function, defined as all of the following:

               1. Left ventricular ejection fraction &gt;50% or within institution normal values.

               2. Absolute neutrophil count (ANC)&gt;1500/mm3.

               3. Platelet count &gt;75,000/mm3

               4. Estimated creatinine clearance&gt;45m1/min.

               5. Total bilirubin&lt;1.5 times institutional ULN (Patients with Gilbert's Syndrome
                  total bilirubin must be &lt;4 times institutional ULN).

               6. Aspartate amino transferase (AST) or alanine amino transferase (ALT) &lt; three
                  times the institutional upper limit of normal (ULN) (if related to liver
                  metastases&lt;five times institutional ULN).

          5. Age ≥ 18 years.

          6. Written informed consent that is consistent with International Conference on
             Harmonization (ICH)-Good Clinical Practice（GCP） guidelines.

        Exclusion Criteria:

          1. Previous anti-cancer treatments including chemotherapy, radiation therapy or targeted
             therapy..

          2. Active symptomatic brain metastases. Dexamethasone therapy will be allowed if
             administered as a stable dose for at least 4 weeks before randomization.

          3. Any other current malignancy or malignancy diagnosed within the past five (5) years.

          4. History or presence of clinically relevant cardiovascular abnormalities such as
             uncontrolled hypertension, congestive heart failure New York Heart Association （NYHA）
             classification of 3, unstable angina or poorly controlled arrhythmia as determined by
             the investigator. Myocardial infarction within 6 months prior to randomisation.

          5. Any other concomitant serious illness or organ system dysfunction which in the opinion
             of the investigator would either compromise patient safety or interfere with the
             evaluation of the safety of the test drug.

          6. Women of child-bearing potential and men who are able to father a child, unwilling to
             be abstinent or use adequate contraception prior to study entry.

          7. Female patients of childbearing potential who are nursing or are pregnant.

          8. Patients unable to comply with the protocol in the opinion of the investigator.

          9. Active hepatitis B infection (defined as presence of Hepatitis B DNA), active
             hepatitis C infection (defined as presence of Hepatitis C RNA) and/or known HIV
             carrier.

         10. Known or suspected active drug or alcohol abuse in the opinion of the investigator.

         11. Major surgery within 4 weeks of starting study treatment. Use of any investigational
             drug within 4 weeks of randomisation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai x Zhang, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tengzhou Center of People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jing w Bi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jinan Military General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin Ye, M.D</last_name>
    <phone>+86 0531-68773172</phone>
    <email>yexintaian2014@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhi g Wei, M.D</last_name>
    <phone>+86 0531-68773171</phone>
    <email>weizhigang321321@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Binzhou Medical University Hospital</name>
      <address>
        <city>Binzhou</city>
        <state>Shandong</state>
        <zip>+86 256600</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shao shui Chen, M.D</last_name>
      <phone>+86 15169959936</phone>
      <email>byfychenss@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dezhou People's Hospital</name>
      <address>
        <city>Dezhou</city>
        <state>Shandong</state>
        <zip>+86 253000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu ting Dong</last_name>
      <phone>+86 13969286066</phone>
      <email>dyt1963@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Dezhou</name>
      <address>
        <city>Dezhou</city>
        <state>Shandong</state>
        <zip>+86 253000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun tang Wang, M.D</last_name>
      <phone>+86 13181378288</phone>
      <email>dzeyxwct@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinan Military General Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>+83 250001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing wang Bi, M.D</last_name>
      <phone>+86 15963119538</phone>
      <email>jingwangbi@outlook.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affliated Hospital of Shandong Academy of Medical Sciences</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>+86 250001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ya hong Sun, M.D</last_name>
      <phone>13606415915</phone>
      <email>sunyahong0915@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>+86 250001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Ye, M.D</last_name>
      <phone>+86 0531-68773171</phone>
      <email>yexintaian2014@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affliated Hospital of Jining Medical University</name>
      <address>
        <city>Jining</city>
        <state>Shandong</state>
        <zip>+86 272000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun ye Wang, M.D</last_name>
      <phone>+86 13563771996</phone>
      <email>jiningwangjunye@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaocheng Cancer Hospital</name>
      <address>
        <city>Liaocheng</city>
        <state>Shandong</state>
        <zip>+86 252000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing liang Feng, M.D</last_name>
      <phone>+86 15339949567</phone>
      <email>fql-123@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Pingyi Country</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <zip>+86 276000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xing lu Xu, M.D</last_name>
      <phone>+86 18265398816</phone>
      <email>xlk2082@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affliated Hospital of Taishan Medical University</name>
      <address>
        <city>Taian</city>
        <state>Shandong</state>
        <zip>+86 271000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben hua Zhang, M.D</last_name>
      <phone>+86 15169887577</phone>
      <email>zhangbenhua1964@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The People's Liberation Army 88 Hospital</name>
      <address>
        <city>Taian</city>
        <state>Shandong</state>
        <zip>+86 271000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li cheng Zhang, M.D</last_name>
      <phone>+86 13605383651</phone>
      <email>zhanglc88@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weifang People's Hospital</name>
      <address>
        <city>Weifang</city>
        <state>Shandong</state>
        <zip>+86 262000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guo hua Yu, M.D</last_name>
      <phone>+86 13685368817</phone>
      <email>ghyry@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yantai Yuhuangding Hospital</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <zip>+86 264000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang ming Zhang, M.D</last_name>
      <phone>+86 18660079893</phone>
      <email>zhanglmdr@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tengzhou center of people's hospital</name>
      <address>
        <city>Zaozhuang</city>
        <state>Shandong</state>
        <zip>+86 277000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai xian Zhang, M.D</last_name>
      <phone>+86 18663069829</phone>
      <email>kaixianzhang@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Wei Z, Ye X, Yang X, Huang G, Li W, Wang J, Han X. Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone. Med Oncol. 2015 Feb;32(2):464. doi: 10.1007/s12032-014-0464-z. Epub 2015 Jan 9.</citation>
    <PMID>25572816</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2015</study_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Xin Ye</investigator_full_name>
    <investigator_title>Chairman of Chinese Anti-Cancer Association Professional Committee of lung cancer minimally invasive therapy combined therapy branch</investigator_title>
  </responsible_party>
  <keyword>microwave ablation</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

